title: Climbing RAS, the everest of oncogenes.
abstract: Mutations that activate the small GTP-binding protein KRAS are the most common oncogenic event in human tumors. Thirty years after its discovery, mutant KRAS has yet to be therapeutically conquered.
authors.affiliation: 1University of Turin, Department of Oncology, Candiolo (TO); 2IRCC, Institute for Cancer Research and Treatment at Candiolo, Candiolo (TO); 3FIRC Institute of Molecular Oncology (IFOM), Milan, Italy.
authors.forename: Mariangela
authors.initials: M
authors.lastname: Russo
authors.forename: Federica
authors.initials: F
authors.lastname: Di Nicolantonio
authors.forename: Alberto
authors.initials: A
authors.lastname: Bardelli
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins